Clovis Oncology is advancing the fight against cancer. Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer. Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado. Please visit our website for more information, including additional office locations in the U.S. and Europe.
View Top Employees from Clovis OncologyWebsite | http://www.clovisoncology.com |
Ticker | CLVS |
Revenue | $145 million |
Funding | $470 million |
Employees | 309 (309 on RocketReach) |
Founded | 2009 |
Address | 5500 Flatiron Parkway, Boulder, Colorado 80301, US |
Phone | (303) 625-5000 |
Fax | (303) 245-0360 |
Technologies |
JavaScript,
HTML,
Twitter
+46 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology Research, Biopharma, Oncology Drug Development, Healthcare, Biotechnology, Drug Discovery, Companion Diagnostics, Health Care, Science and Engineering |
Web Rank | 3 Million |
Keywords | Cancer Treatment, Precision Medicine, Biotechnology, Pharmaceutical Companies, Cancer Research, Cancer Drugs, Oncology, Targeted Cancer Therapies, Solid Tumors |
Competitors | Deciphera Pharmaceuticals, Exelixis, Karyopharm Therapeutics Inc., Puma Biotechnology, Inc., Spectrum Pharmaceuticals, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Clovis Oncology employee's phone or email?
The Clovis Oncology annual revenue was $145 million in 2024.
Paul Gross is the Senior Vice President and General Counsel of Clovis Oncology.
309 people are employed at Clovis Oncology.
Clovis Oncology is based in Boulder, Colorado.
The NAICS codes for Clovis Oncology are [3254, 32541, 32, 325].
The SIC codes for Clovis Oncology are [283, 28].